The Changing Landscape in EGIDs Beyond the Esophagus

SUNDAY, MAY 23, 2021 | 7:15 PM – 8:30 PM EDT

VIRTUAL EVENT

FOR MORE INFORMATION, VISIT
www.medscape.org/symposium/egids-spring-2021

THIS PROGRAM IS NOT AFFILIATED WITH DIGESTIVE DISEASE WEEK®
SPEAKERS

MODERATOR

Evan S. Dellon, MD, MPH
Professor
Department of Medicine
Division of Gastroenterology and Hepatology
Adjunct Professor of Epidemiology
Director, CGIBD Biostatistics and Clinical Research Core
Director, Center for Esophageal Diseases and Swallowing
School of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

DISCLOSURES
Evan S. Dellon, MD, MPH, has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Abbott; Adare; Aimimmune; Allakos; Alimentiv; Amgen; Arena; AstraZeneca; Avir; Biorasi; Bristol Myers Squibb; Calypso; Celgene; Celldex; Ellodi; Eli Lilly; EsoCap; GlaxoSmithKline; Gossamer Bio; Parexel; Receptos; Regeneron; Robarts; Salix; Sanofi; Shire; Takeda

Received grants for clinical research from: Adare; Allakos; AstraZeneca; Bristol Myers Squibb; Celgene; Ellodi; GlaxoSmithKline; Meritage; Miraca; Nutricia; Receptos; Regeneron; Shire; Takeda

Other: Allakos; Banner; Holoclara

PANELISTS

Seema S. Aceves, MD, PhD
Professor, Pediatrics and Medicine
MRD Endowed Chair in Pediatrics
Director, Eosinophilic Gastrointestinal Disorders Clinic
Division of Allergy Immunology
Rady Children’s Hospital San Diego
University of California, San Diego
San Diego, California

DISCLOSURES
Seema S. Aceves, MD, PhD, has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Aimimmune; AstraZeneca; Gossmer Bio; Regeneron

Other: Shire; Takeda

William D. Chey, MD
Nostrant Professor of Gastroenterology
Professor of Nutrition Sciences
Director, Digestive Disorders Integrated Care Program
Director, GI Physiology Laboratory
Michigan Medicine
Ann Arbor, Michigan

DISCLOSURES
William D. Chey, MD, has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Abbvie; Allakos; Alnylam; Arena; BioAmerica; Cosmo; Gemelli; IM Health; Ironwood; Nestlé; QOL Medical; Progenity; Regeneron; Robarts; Salix; Takeda; Urovant; Valeant; Vibrant

Received grants for clinical research from: Commonwealth Diagnostics; NIH; QOL Medical; Salix; Vibrant

Owns stock, stock options, or bonds from: GI OnDemand; ModifyHealth; Ritter

Medscape, LLC staff have disclosed that they have no relevant financial relationships.
OVERVIEW

Eosinophilic gastrointestinal diseases (EGIDs) are serious, chronic, inflammatory digestive disorders characterized by excessive infiltration of eosinophils into gastrointestinal (GI) tissues. Lengthy diagnostic delays are common and often result in disease progression and missed treatment opportunities. In this virtual, live CME event, 3 experts will discuss the pathophysiology, diagnosis, and treatment of EGIDs below the esophagus. They will present the latest evidence for the efficacy of specialized diets and promising emerging pharmacologic agents that may soon alter the course of these diseases for many patients.

AGENDA

7:15 PM
Welcome and Introductions
Evan S. Dellon, MD, MPH

Overview of EGIDs Distal to the Esophagus
Evan S. Dellon, MD, MPH

7:25 PM

EGIDs Below the Esophagus: Making the Diagnosis
Seema S. Aceves, MD, PhD
William D. Chey, MD

7:45 PM
Treatment of EGIDs: Diet, Steroids, and Beyond
Seema S. Aceves, MD, PhD
Evan S. Dellon, MD, MPH

8:10 PM
Concluding Remarks
Evan S. Dellon, MD, MPH

8:15 PM
Audience Q&A

8:30 PM
Backstage Pass Breakout Session
(Optional)

TARGET AUDIENCE

This activity is intended for gastroenterologists, allergists/clinical immunologists, and primary care providers and other healthcare providers (HCPs) involved in the diagnosis and management of patients with eosinophilic gastrointestinal diseases (EGIDs).

LEARNING OBJECTIVES

Upon completion of this activity, participants will:

- Have increased knowledge regarding the
  - Clinical data on emerging treatments for EGIDs
- Have greater competence related to
  - Employing evidence-based diagnostic criteria for EGIDs
  - Selecting treatments for patients with EGIDs
- Demonstrate greater confidence in their ability to
  - Incorporate new and emerging treatments for EGIDs into practice

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enhance Your Virtual Experience With Backstage Pass!

Backstage Pass provides an intimate virtual session where you can interact with faculty, address case-based questions, and facilitate relationship building.

*Video Encouraged*